Half-year report · Q2

Period2025-01-01 → 2025-06-30
Filed2025-08-12
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 42
MetricValuePeriodScopeSource row
Revenue¥252m2025-01-01 → 2025-06-30StandaloneNet sales
Revenue¥781m2024-01-01 → 2024-12-31StandaloneNet sales (5-year summary)
Revenue¥264m2024-01-01 → 2024-06-30StandaloneNet sales
Operating income−¥537m2025-01-01 → 2025-06-30StandaloneOperating income
Operating income−¥581m2024-01-01 → 2024-06-30StandaloneOperating income
Ordinary income−¥539m2025-01-01 → 2025-06-30StandaloneOrdinary income
Ordinary income−¥1.0bn2024-01-01 → 2024-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥563m2024-01-01 → 2024-06-30StandaloneOrdinary income
Profit before tax−¥539m2025-01-01 → 2025-06-30StandaloneIncome before income taxes
Profit before tax−¥562m2024-01-01 → 2024-06-30StandaloneIncome before income taxes
Net income−¥540m2025-01-01 → 2025-06-30StandaloneProfit loss
Net income−¥1.0bn2024-01-01 → 2024-12-31StandaloneNet income loss (5-year summary)
Net income−¥564m2024-01-01 → 2024-06-30StandaloneProfit loss
Total assets¥2.0bnat 2025-06-30StandaloneAssets
Total assets¥2.5bnat 2024-12-31StandaloneAssets
Total assets¥1.6bnat 2024-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥443mat 2025-06-30StandaloneLiabilities
Total liabilities¥549mat 2024-12-31StandaloneLiabilities
Net assets / equity¥1.5bnat 2025-06-30StandaloneNet assets
Net assets / equity¥1.9bnat 2024-12-31StandaloneNet assets
Net assets / equity¥1.1bnat 2024-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.5bnat 2025-06-30StandaloneCash and deposits
Cash and deposits¥2.1bnat 2024-12-31StandaloneCash and deposits
Cash & equivalents¥1.5bnat 2025-06-30StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.1bnat 2024-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31vStandaloneCash and cash equivalents
Operating cash flow−¥673m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.0bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥677m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in operating activities
Financing cash flow¥85m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.7bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥455m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-7.972025-01-01 → 2025-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-17.542024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-10.212024-01-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio76.9%at 2025-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio77.4%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio68.0%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued68,053,800at 2025-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued66,969,000at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued56,387,000at 2024-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥280m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2025-01-01 → 2025-06-30−¥396m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2025-01-01 → 2025-06-30¥252m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2025-01-01 → 2025-06-30¥252m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2025-01-01 → 2025-06-30¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalrevenue external2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalsegment profit2025-01-01 → 2025-06-30−¥257m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥269m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2024-01-01 → 2024-06-30−¥447m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2024-01-01 → 2024-06-30¥135m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-06-30−¥312m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 427
ItemContextValueUnit
Cash and cash equivalents (5-year summary)Prior1QuarterInstant_NonConsolidatedMember1103656000JPY
Cash and cash equivalents (5-year summary)CurrentQuarterInstant_NonConsolidatedMember1474952000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant_NonConsolidatedMember2063280000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember68053800
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember68053800
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant68053800
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant68053800
Number of shares heldCurrentQuarterInstant_No1MajorShareholdersMember1677200
Shareholding ratioCurrentQuarterInstant_No1MajorShareholdersMember0.0246
Number of shares heldCurrentQuarterInstant_No2MajorShareholdersMember1649200
Shareholding ratioCurrentQuarterInstant_No2MajorShareholdersMember0.0242
Number of shares heldCurrentQuarterInstant_No3MajorShareholdersMember1350000
Shareholding ratioCurrentQuarterInstant_No3MajorShareholdersMember0.0198
Number of shares heldCurrentQuarterInstant_No4MajorShareholdersMember962700
Shareholding ratioCurrentQuarterInstant_No4MajorShareholdersMember0.0141
Number of shares heldCurrentQuarterInstant_No5MajorShareholdersMember953500
Shareholding ratioCurrentQuarterInstant_No5MajorShareholdersMember0.0140
Number of shares heldCurrentQuarterInstant_No6MajorShareholdersMember687000
Shareholding ratioCurrentQuarterInstant_No6MajorShareholdersMember0.0100
Number of shares heldCurrentQuarterInstant_No7MajorShareholdersMember527800
Shareholding ratioCurrentQuarterInstant_No7MajorShareholdersMember0.0077
Number of shares heldCurrentQuarterInstant_No8MajorShareholdersMember517000
Shareholding ratioCurrentQuarterInstant_No8MajorShareholdersMember0.0075
Number of shares heldCurrentQuarterInstant_No9MajorShareholdersMember500000
Shareholding ratioCurrentQuarterInstant_No9MajorShareholdersMember0.0073
Number of shares heldCurrentQuarterInstant_No10MajorShareholdersMember443300
Shareholding ratioCurrentQuarterInstant_No10MajorShareholdersMember0.0065
Number of shares heldCurrentQuarterInstant9267700
Shareholding ratioCurrentQuarterInstant0.1362
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember12100
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember68026300
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember680263
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember15400
Number of shares issued shares voting rightsCurrentQuarterInstant68053800
Number of voting rights issued shares voting rightsCurrentQuarterInstant680263
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member12100
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member12100
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.000
Number of shares held in own name treasury shares etcCurrentQuarterInstant12100
Number of shares held in others names treasury shares etcCurrentQuarterInstant-
Total number of shares held treasury shares etcCurrentQuarterInstant12100
Shareholding ratio treasury shares etcCurrentQuarterInstant0.000
Cash and depositsPrior1YearInstant_NonConsolidatedMember2063280000JPY
Cash and depositsCurrentQuarterInstant_NonConsolidatedMember1474952000JPY
Accounts receivable tradePrior1YearInstant_NonConsolidatedMember51063000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2024-12-31pass rounding
balance sheet identitynon_consolidated 2025-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-06-30pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-06-30pass